Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
2(50.0%)
Phase 2
2(50.0%)
4Total
Phase 1(2)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07027345Phase 2Recruiting

A Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex

Role: lead

NCT05062070Phase 1Completed

Safety and Efficacy of Topical TolaSure Targeting Aggregated Mutant Keratin in Severe Epidermolysis Bullosa Simplex

Role: lead

NCT04088357Phase 2Completed

Efficacy of Topical TolaSure on Acute Induced Wounds in Healthy Participants

Role: lead

NCT03620175Phase 1Completed

Safety and Efficacy of Topical TolaSure on Skin Punch Biopsies in Healthy Participants

Role: lead

All 4 trials loaded